Psyence Group (TSE:PSYG)
:PSYG
Top Page
Psyence Group
(PSYG)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.12
▼(-3.33% Downside)
Action:UpgradedDate:12/30/25
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by an improved balance sheet (debt at 0 and equity positive). Technicals remain soft with the stock below key longer-term moving averages, and valuation is constrained by losses and no dividend. A recent RSU incentive program is a small positive but not a fundamental catalyst by itself.
Positive Factors
Strategic Growth Initiatives
The share consolidation aims to provide greater flexibility for business development and growth, potentially improving market positioning and stakeholder interests.
Negative Factors
Financial Instability
The company's financial instability, marked by persistent losses and negative equity, poses significant risks to its ability to sustain operations without external support.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Growth Initiatives
The share consolidation aims to provide greater flexibility for business development and growth, potentially improving market positioning and stakeholder interests.
Read all positive factors
Psyence Group (PSYG) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.88M
Dividend YieldN/A
Average Volume (3M)2.26K
Price to Earnings (P/E)―
Beta (1Y)-0.99
Revenue GrowthN/A
EPS Growth86.48%
CountryCA
Employees21
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding15,638,267
10 Day Avg. Volume3,028
30 Day Avg. Volume2,257
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Psyence Group Business Overview & Revenue Model
Company Description
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical...
How the Company Makes Money
Psyence Group makes money primarily through the development and commercialization of psychedelic therapies. Key revenue streams include licensing agreements with pharmaceutical companies for the use of their psilocybin-based formulations, and part...
Psyence Group Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.61K | -8.46K | -97.93K | -92.27K | -52.64K | -24.50K |
| EBITDA | -15.96M | -5.51M | -5.17M | -5.88M | -4.46M | -3.80M |
| Net Income | -16.00M | -400.23K | -69.45M | -6.08M | -4.60M | -92.51K |
Balance Sheet | ||||||
| Total Assets | 894.70K | 10.60M | 3.27M | 4.00M | 4.35M | 124.51K |
| Cash, Cash Equivalents and Short-Term Investments | 528.11K | 8.89M | 1.06M | 2.38M | 3.49M | 6.10M |
| Total Debt | 0.00 | 0.00 | 12.41M | 47.07K | 1.33M | 56.78K |
| Total Liabilities | 52.20K | 1.06M | 15.11M | 2.67M | 1.64M | 136.77K |
| Stockholders Equity | 842.49K | 1.29M | -23.88M | 1.33M | 2.71M | 6.44M |
Cash Flow | ||||||
| Free Cash Flow | -4.15M | -5.56M | -5.90M | -3.91M | -3.72M | -422.49K |
| Operating Cash Flow | -4.14M | -5.55M | -4.92M | -3.64M | -3.56M | -46.23K |
| Investing Cash Flow | -8.13M | -15.32K | -990.07K | -430.19K | -311.46K | -372.77K |
| Financing Cash Flow | 10.10M | 13.39M | 4.58M | 2.96M | 1.27M | 30.00K |
Psyence Group Technical Analysis
Negative
0.12
Price Trends
0.12
Negative
0.12
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
43.90
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PSYG, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PSYG.
Psyence Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$16.74M | -4.56 | 899.59% | ― | ― | -80.42% | |
47 Neutral | C$1.39M | -3.72 | -107.76% | ― | ― | 34.22% | |
44 Neutral | C$1.88M | -9.19 | ― | ― | ― | 86.48% | |
44 Neutral | C$13.86M | -5.16 | ― | ― | ― | ― |
* Healthcare Sector Average
TSE:PSYG
Psyence Group
0.12
-0.11
-46.67%
TSE:NUMI
Numinus Wellness
0.04
0.00
0.00%
TSE:RVV
Revive Therapeutics
0.04
0.02
100.00%
TSE:ENBI
Entheon Biomedical
0.10
-0.03
-23.08%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
Psyence Group Corporate Events
Business Operations and StrategyM&A Transactions
Psyence Group to Merge with GoldCoast Resource Corp.
Neutral
Nov 24, 2025
Psyence Group Inc. has entered into an amalgamation agreement with GoldCoast Resource Corp. and its subsidiary, Psyence Therapeutics Corp., to form a new entity under the Business Corporations Act of Ontario. This business combination will result ...
Business Operations and StrategyExecutive/Board Changes
Psyence Group Grants RSUs to Key Personnel
Positive
Oct 17, 2025
Psyence Group Inc. announced the grant of 721,448 restricted share units to its executives, officers, directors, and consultants as part of its long-term incentive plan. This move is expected to enhance stakeholder alignment and potentially streng...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.